Team:Potsdam Bioware

From 2012.igem.org

(Difference between revisions)
Line 1: Line 1:
{{:Team:Potsdam_Bioware/header}}
{{:Team:Potsdam_Bioware/header}}
-
 
-
<!--
 
-
<div class="nav_menu">
 
-
{|
 
-
!align="center"|[[Team:Potsdam_Bioware|Home]]
 
-
!align="center"|[[Team:Potsdam_Bioware/Team|Team]]
 
-
!align="center"|[https://igem.org/Team.cgi?year=2012&team_name=Potsdam_Bioware Official Team Profile]
 
-
!align="center"|[[Team:Potsdam_Bioware/Project|Project]]
 
-
!align="center"|[[Team:Potsdam_Bioware/Parts|Parts Submitted to the Registry]]
 
-
!align="center"|[[Team:Potsdam_Bioware/Modeling|Modeling]]
 
-
!align="center"|[[Team:Potsdam_Bioware/Notebook|Notebook]]
 
-
!align="center"|[[Team:Potsdam_Bioware/Safety|Safety]]
 
-
!align="center"|[[Team:Potsdam_Bioware/Attributions|Attributions]]
 
-
|}
 
-
</div>
 
-
-->
 
==Direct Antibody Identification, Maturation and Production in CHO-Cells==
==Direct Antibody Identification, Maturation and Production in CHO-Cells==

Revision as of 10:34, 2 September 2012


Direct Antibody Identification, Maturation and Production in CHO-Cells

Project Description


Antibodies are versatile molecules for research and therapy and they are currently revolutionizing the market of biopharmaceuticals. To date, antibodies are generated in a laborious and time consuming manner. Either animal immunization followed by hybridoma technology or phage display is used to identify desired genes, which then need to be transferred to a production cell line such as CHO. We designed a streamlined workflow that incorporates all steps of antibody generation in CHO cells. Our plan is to stably transfect an antibody-fragment library in CHO cells. Antibody maturation is mimicked by further diversifying this library using the enzyme Activation-Induced cytidine Deaminase (AID), which is known to induce somatic hypermutation. Next, we plan to test and deploy a versatile and continuous viral selection system for clones producing the desired antibodies. Finally, we will try to employ a genetic switch to go from surface expression to soluble production of antibodies.



Team

Mario Köhler
Tom Scheidt
Christopher Kressler
Tobias Priemel
Maria Kunert
Sascha Lehnort
Norman Hein